Trial Profile
A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of Aprepitant for the Prevention of Postoperative Nausea and Vomiting (PONV)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Apr 2019
Price :
$35
*
At a glance
- Drugs Aprepitant (Primary) ; Ondansetron (Primary)
- Indications Postoperative nausea and vomiting
- Focus Therapeutic Use
- Sponsors Merck & Co
- 27 Apr 2019 This study has been discontinued in Lithuania.
- 14 Jun 2011 New trial record